Katiravan J.,Anna University |
Chellappan C.,Anna University |
European Journal of Scientific Research | Year: 2011
Cyber Crime is one of the Major threats for IT Security. Internet Crime refers to criminal exploitation of the Internet. Issues surrounding this type of crime have become high-profile, particularly those surrounding hacking, copyright infringement etc. There are also problems of privacy when confidential information is lost or intercepted, lawfully or otherwise. Existing mechanisms use Packet Marking technique to trace back the real source of attacking packets that traverse through the network. But, this mechanism fails to provide solution in case of IP SPOOFING and Path Failures. In this Paper, we propose a finest solution to trace back the real source using pre-shared key authentication between egress router & the attacker node.
Kumar Madhan K.,PETEC |
Journal of Theoretical and Applied Information Technology | Year: 2014
To many geographic systems (GIS) application scheme such as urban planning and navigation, updating road network database is critical problem. Rapidly changing urban environments accelerate the need for frequent updates or revisions of road network databases. With the advent of high-resolution satellite images, there has been a resurgence of research interest in road extraction techniques. However, due to the extreme complexity of an urban scene, automatic road network extraction continues to be challenging research topic. In this paper, we have proposed a road map extraction system with two efficient filters using satellite images. Here, Unscented Kalman filter (UKF) is used in combination with Gauss-Hermite Kalman Filter (GHKF) to trace and identify various connected road paths and to avoid obstacles under diverse conditions. Unscented Kalman filter (UKF) component is responsible for tracing axis coordinates of a road region until it comes to a severe obstacle or an intersection. Then, the Gauss-Hermite Kalman Filter (GHKF) module takes the control of the road extraction process and regains track of the road or possibly road branches on the other side of a road junction or obstacle. From the results, we ensure that the proposed road extraction technique outperformed the existing approach by achieving the accuracy of 98.452% in cluster 10. © 2005 - 2014 JATIT & LLS. All rights reserved.
Takashi M.,Kyoto University |
Shuichi H.,Kyoto University |
Daisuke O.,Kyoto University |
Masahiko T.,VEC |
Frontiers of Architectural Research | Year: 2013
Various techniques for creating a comfortable thermal environment and saving energy have been proposed and employed in residential buildings in many countries, including Japan. For these techniques to be introduced, existing houses should be renovated. Among the techniques available, installation of additional inner windows is effective in creating a comfortable and energy-efficient living environment. In the present research, the effect of additional inner windows on the thermal environment and energy saving was investigated by measuring indoor climates. Windows were renovated in two rooms on the fourth floor of a four-story reinforced concrete building. Air temperatures, the humidity, the global solar radiation on horizontal and vertical surfaces, radiant temperatures, and the electricity consumption of air-conditioners were measured. A comparison of these values before and after the installation of inner-windows showed that the thermal environment and energy saving had improved. Results obtained from a thermal model agreed well with measured results by changing the value of solar transmittance and heat transmission coefficient of the glazing following renovation. Furthermore, in a questionnaire survey conducted in summer, more than half of the occupants answered "comfortable" to a question on the overall thermal comfort. © 2013 Higher Education Press Limited Company.
Kalirasu A.,Sathyabama University |
Dash S.S.,SRM University |
Lecture Notes in Electrical Engineering | Year: 2015
The main objective of this work is to find the high efficiency DC to DC boost converter for solar power installation system. This paper mainly focuses the modeling of high gain with high efficiency DC to DC boost converter for photovoltaic system under wide input voltage range. The modeling and Matlab simulink simulation of an interleaved and a cascaded DC to DC boost converters are presented. An interleaved and a cascaded DC to DC boost converters are analyzed in open loop and closed loop condition. These converters provide the constant output voltage even the output voltage of the PV panel is continuously varying. The performance of these converters is compared. Based on the comparison result the cascaded boost converter is implemented using PIC microcontroller. This comparison reveals that the cascaded boost converter system has the advantages like reduced number of switching component, low ripple content and high efficiency. © Springer India 2015.
An engineered herpesvirus that provokes an immune response against cancer has become the first treatment of its kind to be approved for use in the United States, paving the way for a long-awaited class of therapies. On 27 October, the US Food and Drug Administration (FDA) approved a genetically engineered virus called talimogene laherparepvec (T-VEC) to treat advanced melanoma. Four days earlier, advisers to the European Medicines Agency had endorsed the drug. With dozens of ongoing clinical trials of similar ‘oncolytic’ viruses, researchers hope that the approval will generate the enthusiasm and cash needed to spur further development of the approach. “The era of the oncolytic virus is probably here,” says Stephen Russell, a cancer researcher and haematologist at the Mayo Clinic in Rochester, Minnesota. “I expect to see a great deal happening over the next few years.” Many viruses preferentially infect cancer cells. Malignancy can suppress normal antiviral responses, and sometimes the mutations that drive tumour growth also make cells more susceptible to infection. Viral infection can thus ravage a tumour while leaving abutting healthy cells untouched, says Brad Thompson, president of the pharmaceutical-development firm Oncolytics Biotech in Calgary, Canada. The strategy builds on a phenomenon that has been appreciated for more than a century. Physicians in the 1800s noted that their cancer patients sometimes unexpectedly went into remission after experiencing a viral infection. These case reports later inspired doctors, particularly in the 1950s and 1960s, to raid nature’s viral cupboard. Clinicians injected cancer patients with a menagerie of viruses. Sometimes the therapy destroyed the tumour, and sometimes it killed the person instead. Unlike the wild viruses used in those mid-twentieth-century experiments, some of today’s anti-cancer viruses are painstakingly engineered. T-VEC, for example, has been altered to drastically reduce its ability to cause herpes. Researchers also inserted a gene encoding a protein that stimulates the immune system, which makes the virus even more potent against cancer (see ‘Going viral against cancer’). As more researchers entered the field and initiated small clinical tests, they began to produce enticing anecdotes. Russell recalls the case of an individual with myeloma who remained sick after undergoing two stem-cell transplants. A tumour on the left side of her forehead had degraded the bone underneath and was putting pressure on her brain. Yet treatment with an experimental virus sent her into complete remission (S. Russell et al. Mayo Clin. Proc. 89, 926–933; 2014). “She’s a star patient who convinced us that this oncolytic paradigm can really work,” he says. But statistics — not anecdotes — rule over drug approvals. In 2005, regulators in China approved an oncolytic adenovirus called H101 to treat head-and-neck cancer, after evidence showed that the treatment could shrink tumours. Those trials stopped short of assessing improvements in patient survival — a measure often required for FDA approval. Since then, a medical-tourism industry has built up in China for people who cannot get the therapy in their home countries. Then, in May this year, a team supported by biotechnology giant Amgen of Thousand Oaks, California, published promising results from a large clinical trial of T-VEC (R. H. Andtbacka et al. J. Clin. Oncol. 33, 2780–2788; 2015). The virus both shrank tumours in people with advanced melanoma and extended patient survival by a median of 4.4 months. Yet statistically, survival benefits fell just a hair’s breadth of significance. “That raised the question, ‘Well, what is statistical significance? Is this an active agent or not?’” Russell says. He and others note that the therapy — which must be injected directly into tumours — seemed to rein in cancer elsewhere in the body as well. This is a sign that results are real and that the virus sparked an immune response as intended, Thompson says. Administering T-VEC in combination with cancer immunotherapy could prove particularly effective, notes Stephen Hodi, an oncologist at the Dana-Farber Cancer Institute in Boston, Massachusetts. In June 2014, a small clinical trial by Amgen suggested that this combination may boost effectiveness over that of the immunotherapies alone. And researchers continue to look for ways to improve T-VEC. In particular, they would like to be able to deliver the therapy systemically, so that the virus could target tumours in organs that are difficult to reach with an injection. This would require a technique to prevent the body from mounting an immune response to the virus prematurely, which would disable it before it could reach and kill tumour cells, says Howard Kaufman, a cancer researcher at Rutgers Cancer Institute of New Jersey. To that end, those in the field are experimenting with a smorgasbord of viruses — from poxviruses to vesicular stomatitis virus, which does not normally infect humans but causes a blistering disease in cattle. Oncolytics Biotech is studying a virus that hitch-hikes through the body on certain blood cells, camouflaged from the immune system. If cancer-killing viruses could be delivered to their targets through the bloodstream, rather than via injection directly into the tumour, they could be used to treat a greater range of cancers. Thompson envisions a day when physicians will be able to peruse a menu of oncolytic viruses and select the best fit. “Each virus interacts with the immune system differently,” he says. “They could have a role in pretty much all cancer therapy.”